ResMed
677 hedge funds and large institutions have $20.9B invested in ResMed in 2023 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 235 increasing their positions, 268 reducing their positions, and 86 closing their positions.
73% more call options, than puts
Call options by funds: $43.6M | Put options by funds: $25.2M
6% more capital invested
Capital invested by funds: $19.7B → $20.9B (+$1.19B)
0.03% more ownership
Funds ownership: 64.7% → 64.74% (+0.03%)
7% less funds holding
Funds holding: 730 → 677 (-53)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
12% less repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 268
47% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 86
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$219M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$204M |
| 3 |
Holocene Advisors
New York
|
+$141M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$66.1M |
| 5 |
Amundi
Paris,
France
|
+$49.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$173M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$102M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$87.6M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$80.7M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
-$76.2M |
RMD Hedge Fund Activity: Q1 2023 in Review
677 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q1 2023, worth a combined $20.9B — up 6% from $19.7B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of RMD and 46 opened new positions — a net loss of 40 holders — while 268 trimmed existing stakes and 235 added.
The largest buyer was Vanguard Group, adding an estimated $219M. The largest seller was Capital World Investors, cutting an estimated $173M.
- 677 institutional investors held ResMed (RMD) as of Q1 2023, down from 730 in Q4 2022.
- Funds reported $20.9B of ResMed stock for Q1 2023, up 6% quarter-over-quarter.
- 46 funds opened new ResMed positions in Q1 2023 and 86 closed out, a net change of -40 holders.
- The largest ResMed buyer in Q1 2023 was Vanguard Group, an estimated $219M added.
- The largest ResMed seller in Q1 2023 was Capital World Investors, an estimated $173M sold.
Based on aggregated 13F filings for Q1 2023.